Log In
Print this Print this

HER2 IQFISH pharmDx test

  Manage Alerts
Collapse Summary General Information
Company Agilent Technologies Inc.
DescriptionFluorescent in situ hybridization (FISH) assay based on Dako's IQISH hybridization buffer that allows for a turnaround time of about three and a half hours
Molecular Target
Mechanism of ActionDiagnostic
Therapeutic ModalityDiagnostics
Latest Stage of DevelopmentMarketed
Standard IndicationCancer, Diagnostic
Indication DetailsAid in the assessment of patients for whom Herceptin trastuzumab is being considered; Identify patients with HER-2 positive metastatic breast cancer who may be eligible for treatment with Kadcyla ado-trastuzumab emtansine
Regulatory Designation

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today